Isovalerylcarnitine C5

When isovaleryl-CoA dehydrogenase is deficient, isovaleryl-CoA cannot be handled normally and accumulates. Carnitine then conjugates with the excess substrate, forming isovalerylcarnitine and linking the biochemical disturbance to the measurable C5 signal. This relationship makes C5 useful as an indicator of impaired leucine breakdown rather than as a nonspecific marker of illness.

Some medications produce pivaloylcarnitine, which can generate a C5 signal similar to that associated with isovalerylcarnitine. Consequently, a detected C5 elevation requires consideration of medication exposure alongside the metabolic findings. This distinction matters because the same analytical signal can reflect different biochemical sources, making clinical context essential when evaluating a screening result.

An infection can precipitate decompensation in a patient at risk from toxic organic acid accumulation. In this setting, C5 measurement contributes to identifying the underlying metabolic vulnerability, while clinical findings and context remain important for interpretation. The marker therefore connects metabolic screening with recognition of patients who may become clinically unstable during infectious illness.

Testing begins with a dried blood spot, which provides the blood specimen for analysis. Tandem mass spectrometry then detects the C5 signal associated with isovalerylcarnitine. This workflow supports newborn screening by identifying a biochemical pattern that can signal risk for toxic organic acid accumulation, metabolic acidosis, and infection-triggered decompensation.

Interpretation should account for the patient’s clinical context and possible medication exposure. Pivaloylcarnitine from some medications can produce a similar C5 signal, so the result should not be viewed in isolation. Considering these alternatives helps distinguish a pattern related to disrupted leucine breakdown from an analytically similar signal with a different biochemical source.

C5 testing provides metabolic context when infection-related clinical deterioration raises concern for an underlying organic acid disorder. It can help identify patients at risk for toxic accumulation and metabolic acidosis, conditions that may complicate infectious illness. Its value in this subject area lies in linking infection-triggered decompensation with a measurable disturbance in leucine breakdown.